We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Clinical Significance of Myosteatosis in Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib.
- Authors
Kang, Min Kyu; Song, Jeong Eun; Jang, Se Young; Kim, Byung Seok; Chung, Woo Jin; Lee, Changhyeong; Park, Soo Young; Tak, Won Young; Kweon, Young Oh; Hwang, Jae Seok; Jang, Byoung Kuk; Lee, Yu Rim; Park, Jung Gil
- Abstract
Simple Summary: Research on the clinical impact of body composition parameters, such as myosteatosis, in patients with hepatocellular carcinoma (HCC) is limited. Our study examined the effects of computed tomography-based body composition measurements and traditional risk factors on the survival outcomes of sorafenib-treated HCC patients. Myosteatosis, evaluated using Hounsfield units, is associated with unfavorable survival outcomes, independent of traditional risk factors including vascular invasion, extrahepatic metastasis, and high alpha-fetoprotein levels. Two or more of these risk factors are associated with adverse outcomes. Thus, myosteatosis could serve as a prognostic factor in sorafenib-treated HCC patients. The role of body composition parameters in sorafenib-treated hepatocellular carcinoma (HCC) patients is still not fully elucidated. Here, we aimed to evaluate the impact of computed tomography (CT)-based body composition parameters on the survival of such patients. In this multicenter study, we analyzed the data of 245 sorafenib-treated HCC patients from January 2008 to December 2019. Sarcopenia, visceral obesity, and myosteatosis were defined by using cross-sectional CT images at the third lumbar vertebra level. The effects of these parameters on overall survival (OS) and progression-free survival (PFS) were evaluated. The median age was 67.0 years (interquartile range: 61.0–78.0 year), and 211 patients (86.1%) were male. The median OS and PFS were 7.9 months and 4.8 months, respectively. Vascular invasion (hazard ratio (HR), 1.727; 95% confidence interval (CI), 1.258–2.371; p = 0.001), extrahepatic metastasis (HR, 1.401; 95% CI, 1.028–1.908; p = 0.033), alpha-fetoprotein level > 200 ng/mL (HR, 1.559; 95% CI, 1.105–2.201; p = 0.012), and myosteatosis (HR, 1.814; 95% CI, 1.112–2.960; p = 0.017) were associated with OS. Patient mortality was significantly higher in the group with two or more risk factors than in the group with fewer risk factors. In conclusion, myosteatosis may be a novel prognostic CT-based radiological biomarker in sorafenib-treated HCC patients.
- Subjects
BODY composition; CONFIDENCE intervals; ANTHROPOMETRY; CROSS-sectional method; CANCER patients; COMPARATIVE studies; SORAFENIB; SURVIVAL analysis (Biometry); DESCRIPTIVE statistics; RESEARCH funding; COMPUTED tomography; TUMOR markers; ODDS ratio; HEPATOCELLULAR carcinoma
- Publication
Cancers, 2024, Vol 16, Issue 2, p454
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers16020454